Latest news for Accustem Sciences (OTC:ACUT) Stock

Accustem Sciences Inc is a life sciences company that focuses on enhancing cancer patient outcomes through diagnostic, pharmaceutical, and medical device products. The company's product, StemPrintER, is a genomic platform for predicting distant recurrence risk in luminal, ER+/HER2-negative breast cancer patients. Additionally, It offers ancillary commodity testing to provide further insights. Validated in various retrospective cohorts, StemPrintER shows promise for oncology clinics. Revenue is generated through product commercialization and testing services. Operations span New York, NY, and London, UK.

Long Ideas

News

Penny Stocks

Insider Trades

Markets

Trading Ideas

ACUT

AUGG

BJDX

RYES

US crude oil futures traded lower this morning on Thursday. Investors, meanwhile, focused on some notable insider trades.

When insiders purchase or sell shares, it indicates their confidence or concern around the company&#39;s prospects. Investors and traders interested in penny stocks can consider this a factor in their overall investment or trading decision.

4 Stocks Under $2 Insiders Are Aggressively Buying

ACCUSTEM SCIENCES INC by Accustem Sciences Inc.

Accustem Sciences Inc

ACUTUS MEDICAL INC by Acutus Medical Inc.

Acutus Medical Inc

Earnings

SEED

Origin Agritech FY24 EPS $0.46 Down From $1.17 YoY, Sales $16.18M Up From $13.00M YoY

Motorola Solns (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MSI#NYSE">MSI</a>) has outperformed the market over the past 20 years by 27.45% on an annualized basis producing an average annual return of 35.86%. Currently, Motorola Solns has a market capitalization of $80.51 billion. 
Buying $1000 In MSI: If an investor had bought $1000 of MSI stock 20 years ago, it would be worth $476,990.10 today based on a price of $481.76 for MSI at the time of writing.
<h3>Motorola Solns's Performance Over Last 20 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1739227510_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Here's How Much $1000 Invested In Motorola Solns 20 Years Ago Would Be Worth Today

Rosenblatt analyst Barton Crockett maintains Lions Gate Enter (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LGF#NYSE">LGF</a>) with a Buy and maintains $13 price target.

Price Target

Analyst Ratings

Lions Gate Entertainment Corporation Class B Non-Voting Shares

LGF/B

Rosenblatt Maintains Buy on Lions Gate Enter, Maintains $13 Price Target

FreeCast's streaming platform will be available to users of the Company's mobile device portfolio. The new integration will give Foxx Development's users immediate access to FreeCast's entertainment hub, consolidating hundreds of streaming services into a single user-friendly interface.

FOXX

Foxx Development Enters Strategic Distribution Agreement With FreeCast

Coca-Cola Company (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/KO#NYSE">KO</a>) has a history of beating analyst estimates in recent quarters and looks to keep the streak alive with its fourth-quarter financial results before <a href="https://www.benzinga.com/earnings">the market opens Tuesday</a>.
Earnings Estimates: Analysts expect Coca-Cola to report fourth-quarter earnings per share of 52 cents. That&#8217;s up from 49 cents in last year's fourth quarter, according to data<a href="https://bzresearch.myclickfunnels.com/benzinga-pro-content-webinar-registration/?utm_source=BZprocontent021025&amp;t=be2bearmibe3na1"> from Benzinga Pro.</a>
The company has beaten analyst estimates for earnings per share in three straight quarters and eight of the last 10 quarters overall. The other two quarters the company didn't beat estimates, the results were in-line with analysts.
Analysts expect Coca-Cola to report fourth-quarter revenue of $10.68 billion, down from $10.85 billion in last year's fourth quarter.
The Atlanta-based company has beaten analyst estimates for revenue in 15 straight quarters, according to Benzinga Pro data.
Read Also: <a href="https://www.benzinga.com/trading-ideas/technicals/25/02/43605038/coca-cola-stock-is-bubbling-higher-can-q4-earnings-keep-the-fizz-going">Coca-Cola Stock Is Bubbling Higher: Can Q4 Earnings Keep The Fizz Going?</a>
What Analysts Are Saying: Piper Sandler analyst Michael Lavery said Coca-Cola has attractive and sustainable growth drivers. In an investor note last month, he highlighted the North America and Latin America regions for seeing strong growth that can be sustainable over the long term.
Lavery initiated coverage on the stock with an Overweight rating and a $74 price target, which was later revised down to $73 later in January.
The analyst said the North America and Latin America regions still have a large percentage of their populations that do not drink commercial beverages, offering an expansion opportunity.
Rising incomes in emerging markets along with population growth could be long-term drivers for "sustainable volume and pricing gains," Lavery said.
Here are other recent<a href="https://www.benzinga.com/quote/KO/analyst-ratings"> analyst ratings on Coca-Cola</a> and their price targets.
<ul>
<li>RBC Capital: Reiterated Outperform rating, raised price target from $68 to $69</li>
<li>Jefferies: Upgraded from Hold to Buy, raised price target from $69 to $75</li>
<li>JPMorgan: Maintained Overweight rating, lowered price target from $75 to $70</li>
<li>Barclays: Maintained Overweight rating, lowered price target from $73 to $66</li>
</ul>
Key Items to Watch: Coca-Cola's earnings report comes after rival PepsiCo (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PEP#NASDAQ">PEP</a>) recently<a href="https://www.benzinga.com/25/02/43460249/pepsicos-q4-sales-miss-estimates-on-downcast-performance-in-north-america-stock-dives"> reported fourth-quarter financial results. </a>Pepsi shares fell after the report with the company missing analyst estimates.
While Pepsi competes in both the beverage and food markets, the company's North American PepsiCo division is most comparable with the beverage unit of Coca-Cola in North America. This segment saw flat revenue in the quarter for Pepsi.
Coca-Cola's report could include a look at inflation, consumer spending habits and more on how higher prices for several grocery items are impacting spending on beverages.
The beverage giant is a key market indicator as a member of the Dow Jones Industrial Average, although the company's lower share price makes the stock the 28th largest weighting of 30 stocks.
The company's earnings report will also be closely watched by legendary investor Warren Buffett and Berkshire Hathaway Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BRK#NYSE">BRK</a>)(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BRK#NYSE">BRK</a>).
Berkshire Hathaway owns 400 million Coca-Cola shares. The stock is one of the largest holdings of the legendary investor's conglomerate.
Investors and analysts, and maybe Buffett, will be interested to hear if Coca-Cola provides an update on 2025 guidance. <a href="https://www.benzinga.com/news/earnings/24/10/41486650/coca-cola-q3-earnings-eps-beat-pricing-growth-offset-by-volume-decline-sees-10-q4-organic-revenue-g">The company expects</a> adjusted net revenue and earnings per share to have a low single-digit and mid-single-digit currency headwind, respectively.
Price Action: Coca-Cola stock was up 1.1% to $64.55 on Monday versus a 52-week trading range of $57.93 to $73.53. Coca-Cola stock is up 7.5% over the last year.
Shares of rival Pepsi trade at $143.73 versus a 52-week trading range of $141.51 to $183.39. Pepsi stock is down 15.8% over the last year.
Both Coca-Cola and Pepsi shares have underperformed the S&amp;P 500. The SPDR S&amp;P 500 ETF Trust is up 20.7% over the past year.
Read Next: 
<ul>
<li><a href="https://www.benzinga.com/news/earnings/25/02/43591420/how-to-earn-500-a-month-from-coca-cola-stock-ahead-of-q4-earnings">How To Earn $500 A Month From Coca-Cola Stock Ahead Of Q4 Earnings</a></li>
</ul>
Image: Shutterstock

Previews

Coca-Cola Q4 Earnings Preview: Can Warren Buffett Favorite Keep Streak Of Revenue Beats Alive?

Rosenblatt analyst Barton Crockett maintains Walt Disney (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DIS#NYSE">DIS</a>) with a Buy and maintains $135 price target.

Rosenblatt Maintains Buy on Walt Disney, Maintains $135 Price Target

Verisk Analytics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VRSK#NASDAQ">VRSK</a>) has outperformed the market over the past 15 years by 4.86% on an annualized basis producing an average annual return of 16.9%. Currently, Verisk Analytics has a market capitalization of $41.52 billion. 
Buying $1000 In VRSK: If an investor had bought $1000 of VRSK stock 15 years ago, it would be worth $10,407.08 today based on a price of $294.00 for VRSK at the time of writing.
<h3>Verisk Analytics's Performance Over Last 15 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1739226617_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

VRSK

Here's How Much $1000 Invested In Verisk Analytics 15 Years Ago Would Be Worth Today

Mild winter weather for the first two months of the quarter contributed to a softer quarter than had been assumed in the company's original forecast.&nbsp;

Guidance

Compass Minerals Cuts 2025 Salt Segment Revenue Outlook From $940M - $1.04B To $900M - $1B

Rosenblatt analyst Hans Mosesmann maintains Lattice Semiconductor (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LSCC#NASDAQ">LSCC</a>) with a Buy and maintains $85 price target.

LSCC

Rosenblatt Maintains Buy on Lattice Semiconductor, Maintains $85 Price Target

Compass Minerals Intl (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CMP#NYSE">CMP</a>) reported quarterly losses of $(0.55) per share which missed the analyst consensus estimate of $0.15 by 466.67 percent. The company reported quarterly sales of $307.20 million which beat the analyst consensus estimate of $294.00 million by 4.49 percent. This is a 10.10 percent decrease over sales of $341.70 million the same period last year.

Earnings Beats

Earnings Misses

Compass Minerals Intl Q1 2025 Adj EPS $(0.55) Misses $0.15 Estimate, Sales $307.20M Beat $294.00M Estimate

MARA

MARA Holding Postpones Special Meeting Of Stockholders To February 19, 2025

RCUS

Arcus Biosciences Plans To Present New Data from Casdatifan Via Oral Presentation At 2025 ASCO GU Symposium

&nbsp;S&amp;P 500 constituent Blackstone Inc. is acquiring Retail Opportunity Investments in a deal expected to be completed soon, pending final closing conditions.&nbsp;

GOLF

ROIC

Acushnet Holdings To Replace Retail Opportunity Investments In S&P SmallCap 600 Effective Prior To Opening Of Trading On February 13

EVI Industries Q2 EPS $0.07 Down From $0.09 YoY, Sales $92.7M Up From $91.36M YoY

Goldman Sachs Gr (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GS#NYSE">GS</a>) has outperformed the market over the past 5 years by 10.02% on an annualized basis producing an average annual return of 22.37%. Currently, Goldman Sachs Gr has a market capitalization of $201.96 billion. 
Buying $100 In GS: If an investor had bought $100 of GS stock 5 years ago, it would be worth $272.93 today based on a price of $650.53 for GS at the time of writing.
<h3>Goldman Sachs Gr's Performance Over Last 5 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1739225713_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Here's How Much You Would Have Made Owning Goldman Sachs Gr Stock In The Last 5 Years

LIXT

LIXTE Biotechnology Submits Request For Withdrawal Of Form S-1 Registration Statement; No Longer Intends To Pursue Public Offering AT This Time

Based on discussions with the Staff, because the Company met the Minimum Bid Price Requirement for 10 consecutive business days as of February 7, 2025, it expects that the Staff would confirm the Company has regained compliance, allowing its common stock to continue trading on Nasdaq without interruption and obviating the need for appealing the delisting determination.

GITS

Global Interactive Technologies Reveals Receipt Of Determination Letter From Nasdaq; Expects Nasdaq Staff Would Confirm Company Has Regained Compliance

Medpace Holdings Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MEDP#NASDAQ">MEDP</a>) reported fourth-quarter financial results after the market close on Monday. Here&#8217;s a rundown <a href="https://www.benzinga.com/pressreleases/25/02/b43608551/medpace-holdings-inc-reports-fourth-quarter-and-full-year-2024-results">of the report</a>.
<ul>
<li>Q4 Revenue: $536.6 million, versus <a href="https://www.benzinga.com/calendars/earnings">estimates</a> of $534.78 million</li>
</ul>
<ul>
<li>Q4 EPS: $3.67, versus estimates of $2.96</li>
</ul>
Total revenue was up 7.7% on a year-over-year basis. New business awards totaled $529.7 million in the quarter, down 13.8% year-over-year. The company ended the period with a backlog of approximately $2.9 billion, up 3.2% year-over-year. 
Medpace generated $190.7 million in cash flow from operations during the quarter. The company had cash and cash equivalents of $669.4 million as of Dec. 31.
Medpace said it repurchased $174.2 million of its common stock during the quarter. The company had $134.6 million remaining under its buyback at quarter&#8217;s end. Additionally, Medpace&#8217;s board approved an increase of $600 million to the company&#8217;s buyback program on Feb. 6. 
Check This Out: <a href="https://www.benzinga.com/25/02/43608715/lattice-semiconductor-shares-jump-after-mixed-q4-results-strong-q1-guidance#google_vignette">Lattice Semiconductor Shares Jump After Mixed Q4 Results, Strong Q1 Guidance</a>
Outlook: Medpace expects full-year 2025 revenue to be in the range of $2.11 billion to $2.21 billion. The company sees full-year earnings in the range of $11.93 per share to $12.69 per share. 
Medpace executives will further discuss the quarter on a call with investors and analysts at 9 a.m. ET Tuesday morning.
MEDP Price Action: At publication time Monday, <a href="http://benzinga.com/quote/medp">Medpace shares</a> were down 8.33% at $324.97 in after-hours trading, according to <a href="http://pro.benzinga.com">Benzinga Pro</a>.
Photo: Shutterstock.

Movers

MEDP

Medpace Stock Falls On Q4 Earnings: The Details

Management

Southwest Airlines Names Tom Doxey As Executive Vice President & CFO, Effective March 10

Stock Split

TANH

Tantech Holdings Says Board Approved On January 21 To Effect Share Consolidation Of Common Shares At 1-For-40 Ratio With Effective Date Of February 13

Press Releases

AccuStem Sciences, Inc. Announces Chairman Purchase of Shares

Accustem Sciences

US crude oil futures traded lower this morning on Thursday. Investors, meanwhile, focused on some notable insider trades.

When insiders purchase or sell shares, it indicates their confidence or concern around the company&#39;s prospects. Investors and traders interested in penny stocks can consider this a factor in their overall investment or trading decision.

Below is a look at a few recent notable insider transactions for penny stocks. For more, check out <a href="https://www.benzinga.com/sec/insider-trades/"> Benzinga&#39;s insider transactions </a> platform.

<h2>Bluejay Diagnostics </h2>

<ul>
	<li>The Trade: Bluejay Diagnostics, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BJDX#NASDAQ">BJDX</a>) Chief Financial Officer Kenneth Fisher <a href="https://www.benzinga.com/sec/insider-trades/"> acquired a total of 20,000 shares </a> at an average price of $0.99. To acquire these shares, it cost $19.8 thousand.</li>
	<li>What&rsquo;s Happening: Bluejay Diagnostics recently posted a Q1 loss of $0.10 per share.</li>
	<li>What Bluejay Diagnostics Does: Bluejay Diagnostics Inc develops, manufactures and markets innovative clinical diagnostic products that improve the quality of medical diagnoses by developing Point-of-Care tests that provide convenience, timeliness, compliance and low cost to physicians and patients in areas where timeliness of the initial triage assessment has a high impact on course of treatment.</li>
</ul>

<h2>Rise Gold </h2>

<ul>
	<li>The Trade: Rise Gold Corp. (OTC:<a class="ticker" href="https://www.benzinga.com/stock/RYES#OTC">RYES</a>) Director Lawrence W. Lepard <a href="https://www.benzinga.com/sec/insider-trades/"> acquired a total of 216,500 shares </a> at an average price of $0.51. The insider spent around $110.59 thousand to buy those shares.</li>
	<li>What&rsquo;s Happening: Rise Gold recently reported progress on Idaho-Maryland use permit.</li>
	<li>What Rise Gold Does: Rise Gold Corp is a mineral exploration stage mining company and its primary asset is a major past producing Idaho-Maryland Gold Mine property near Grass Valley, California, United States.</li>
</ul>

<a href="https://www.benzinga.com/trading-ideas/long-ideas/22/04/26834505/executives-buy-around-413m-of-3-stocks">Also check this: Executives Buy Around $413M Of 3 Stocks </a>

Don&rsquo;t forget to check out our <a href="https://www.benzinga.com/premarket/"> premarket coverage here </a>.

<h2>Augusta Gold </h2>

<ul>
	<li>The Trade: Augusta Gold Corp. (OTC:<a class="ticker" href="https://www.benzinga.com/stock/AUGG#OTC">AUGG</a>) Director Augusta Investments Inc <a href="https://www.benzinga.com/sec/insider-trades/"> acquired a total of 22,500 shares </a> at an average price of $1.14. To acquire these shares, it cost around $25.61 thousand.</li>
	<li>What&rsquo;s Happening: The company&rsquo;s stock has gained 35% since the start of the year.</li>
	<li>What Augusta Gold Does: Augusta Gold Corp is an exploration stage company. The company is primarily engaged in the acquisition and exploration of gold properties.</li>
</ul>

<h2>Accustem Sciences </h2>

<ul>
	<li>The Trade: Accustem Sciences Inc. (OTC:<a class="ticker" href="https://www.benzinga.com/stock/ACUT#OTC">ACUT</a>) Director Gabriele M Cerrone <a href="https://www.benzinga.com/sec/insider-trades/"> acquired a total of 9,447 shares </a> at an average price of $1.43. The insider spent $13.49 thousand to buy those shares.</li>
	<li>What&rsquo;s Happening: AccuStem recently reported a private placement of common stock.</li>
	<li>What Accustem Sciences Does: Accustem Sciences Inc is a life sciences company dedicated to optimizing outcomes for all patients with cancer across the globe.</li>
</ul>

Comments

Accustem Sciences

News

Latest news for Accustem Sciences (OTC:ACUT) Stock

Thursday, April 28, 2022

Popular Channels

Tools & Features

Partners & Contributors

About Benzinga